<DOC>
	<DOC>NCT02589626</DOC>
	<brief_summary>This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control</brief_summary>
	<brief_title>Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of type 2 diabetes mellitus Male and female patients on diet and exercise regimen who are pretreated with Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be &gt;=7.0% and &lt;=10.0% at screening Male and female patients on diet and exercise regimen who are pretreated with Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10 weeks prior to Visit 1 must be &gt;=7.0% and &lt;=9.0% at screening and &gt;=7.0% and &lt;=10.0% at placebo runin Male and female patients on diet and exercise regimen who are pretreated with OAD alone for at least 10 weeks prior to Visit 1 must be &gt;=7.0% and &lt;=10.0% at both screening and placebo runin Age at informed consent must be &gt;=20 years BMI at screening must be &lt;=40 kg/m2 Further inclusion criteria apply Exclusion criteria: Uncontrolled hyperglycaemia with a glucose values &gt;270 mg/dL (&gt;15.0 mmol/L) after an overnight fast during switch/washout/placebo runin period and confirmed by a second measurement Patients who are drugna√Øve at screening visit or treat with any of insulin, thiazolidine dione, SGLT2 inhibitor within 10 weeks prior to informed consent. Acute coronary syndrome, stroke or transient ischemic attack within 12 weeks prior to informed consent Indication of liver disease, defined by serum levels of either alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal as determined during screening and/or switch/washout/placebo runin period Impaired renal function, defined as eGFR &lt;45 mL/min/1.73m2 (Japanese equation) as determined during screening and/or switch/washout/placebo runin period Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>